• SPX
  • $5,738.17
  • -0.13 %
  • -$7.20
  • DJI
  • $42,313.00
  • 0.33 %
  • $137.89
  • N225
  • $39,829.56
  • 2.32 %
  • $903.93
  • FTSE
  • $8,320.76
  • 0.43 %
  • $35.85
  • IXIC
  • $18,119.59
  • -0.39 %
  • -$70.70
Eli Lilly and Company (LLY) Stock Price, News & Analysis

Eli Lilly and Company (LLY) Stock Price, News & Analysis

Currency in USD Disclaimer

$877.61

-$31.71

(-3.49%)

Day's range
$875.61
Day's range
$901.21
50-day range
$747.55
Day's range
$972.53
  • Country: US
  • ISIN: US5324571083
52 wk range
$516.57
Day's range
$972.53


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 10.21
  • Piotroski Score 5.00
  • Grade Overweight
  • Symbol (LLY)
  • Company Eli Lilly and Company
  • Price $877.61
  • Changes Percentage (-3.49%)
  • Change -$31.71
  • Day Low $875.61
  • Day High $901.21
  • Year High $972.53

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

  • Last Earnings 06/24/2024
  • Ex-Dividend for 5/16 Dividend 08/15/2024
  • Dividend Payable 09/10/2024
  • Today N/A
  • Next Earnings (Estimated) 10/30/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $870.50
  • High Stock Price Target $1,150.00
  • Low Stock Price Target $300.00
  • Potential Upside/Downside N/A
  • Consensus Rating Neutral
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) $6.78
  • Trailing P/E Ratio 125.37
  • Forward P/E Ratio 125.37
  • P/E Growth 125.37
  • Net Income $5.24 B

Income Statement

Quarterly

Annual

Latest News of LLY

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to StockNews!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.